EGFR binding proteins

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10858405
APP PUB NO 20180030098A1
SERIAL NO

15548976

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin®), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NAVIGO PROTEINS GMBH06120 HALLE/SAALE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bosse-Doenecke, Eva Halle/Saale, DE 14 32
Fiedler, Erik Halle/Saale, DE 35 170
Haupts, Ulrich Halle/Saale, DE 37 385
Settele, Florian Halle/Saale, DE 6 22

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 8, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 8, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00